Amesite Launches NurseMagic™ Pilot Programs with Five Healthcare Companies
September 12, 2024 07:30 ET
|
Amesite Inc.
DETROIT, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, announced...
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
September 12, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on...
Oruka Therapeutics Announces $200 Million Private Placement
September 12, 2024 07:05 ET
|
Oruka Therapeutics, Inc.
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new...
OrthoPediatrics Corp. Announces Launch of Enabling Technologies Division
September 12, 2024 07:05 ET
|
OrthoPediatrics Corp.
WARSAW, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced...
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
September 12, 2024 07:01 ET
|
Invivyd
Centers for Disease Control and Prevention (CDC) reports death rate due to COVID-19 has continued to increase throughout 2024 Immunocompromised patients at greatest risk for serious infections or even...
Lifecore Biomedical Regains Compliance with Nasdaq Listing Requirements
September 12, 2024 07:00 ET
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization...
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
September 12, 2024 07:00 ET
|
Oruka Therapeutics, Inc.
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human...
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
September 12, 2024 07:00 ET
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
Climb Channel Solutions Announces Keyfactor as New North American Channel Partner
September 12, 2024 07:00 ET
|
Climb Channel Solutions
EATONTOWN, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ:...
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
September 12, 2024 07:00 ET
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...